Ascendis Pharma A/S (NASDAQ:ASND) Given Average Recommendation of “Moderate Buy” by Analysts

Ascendis Pharma A/S (NASDAQ:ASND) has received an average rating of “Moderate Buy” from the fourteen brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $192.07.

Several research firms have recently commented on ASND. JPMorgan Chase & Co. decreased their price objective on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. TD Cowen reduced their price target on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a report on Friday, November 15th. Bank of America lifted their target price on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. UBS Group started coverage on Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price target for the company. Finally, Stifel Nicolaus upped their target price on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research report on Friday, November 15th.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors have recently made changes to their positions in ASND. Wilmington Savings Fund Society FSB purchased a new position in Ascendis Pharma A/S in the 3rd quarter valued at approximately $30,000. GAMMA Investing LLC lifted its holdings in Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 214 shares during the period. Signaturefd LLC increased its stake in Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 80 shares in the last quarter. Pursue Wealth Partners LLC acquired a new position in shares of Ascendis Pharma A/S during the 3rd quarter worth $217,000. Finally, Rhumbline Advisers raised its position in shares of Ascendis Pharma A/S by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 143 shares during the last quarter.

Ascendis Pharma A/S Stock Up 2.5 %

NASDAQ ASND opened at $134.87 on Thursday. The firm’s 50-day simple moving average is $132.84 and its two-hundred day simple moving average is $133.54. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $161.00. The company has a market cap of $8.19 billion, a PE ratio of -16.69 and a beta of 0.65.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.